Lexeo Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Otero Jose Manuel
Lexeo Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Townsend Richard Nolan
Lexeo Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics | 10-Q: Quarterly report
Lexeo Therapeutics | ARS: Annual Report to Security Holders
Lexeo Therapeutics | DEFA14A: Others
Lexeo Therapeutics | DEF 14A: Definitive information statements
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | 8-K: Current report
Lexeo Therapeutics | EFFECT: Others
Lexeo Therapeutics | 424B3: Prospectus
Lexeo Therapeutics | UPLOAD: Others
Lexeo Therapeutics | CORRESP: CORRESP
Lexeo Therapeutics | S-1: General form for registration of securities under the Securities Act of 1933
No Data